Attention Deficit Hyperactivity Disorder (ADHD) News and Research RSS Feed - Attention Deficit Hyperactivity Disorder (ADHD) News and Research Twitter

Attention deficit-hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 3-5 percent of all American children. It interferes with a person's ability to stay on a task and to exercise age-appropriate inhibition (cognitive alone or both cognitive and behavioral). Some of the warning signs of ADHD include failure to listen to instructions, inability to organize oneself and school work, fidgeting with hands and feet, talking too much, leaving projects, chores and homework unfinished, and having trouble paying attention to and responding to details. There are several types of ADHD: a predominantly inattentive subtype, a predominantly hyperactive-impulsive subtype, and a combined subtype. ADHD is usually diagnosed in childhood, although the condition can continue into the adult years.
New study gives insight into the mental health of teens, children with Down syndrome

New study gives insight into the mental health of teens, children with Down syndrome

A new study gives insight into the mental health of children and teens with Down syndrome and the behavioral medications that medical caregivers sometimes prescribe for them. [More]
Study finds link between pyrethroid pesticide exposure and ADHD in children, teens

Study finds link between pyrethroid pesticide exposure and ADHD in children, teens

A new study links a commonly used household pesticide with attention deficit hyperactivity disorder (ADHD) in children and young teens. [More]
Adult ADHD could be distinct condition

Adult ADHD could be distinct condition

Longitudinal analysis of a birth cohort raises the possibility that attention deficit/hyperactivity disorder in children and in adults may be distinct and unrelated disorders. [More]
Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Today, Rhodes Pharmaceuticals L.P. announced that Aptensio XR, a once-daily central nervous system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will be available to patients beginning Summer 2015. [More]
Genes influence ADHD course

Genes influence ADHD course

A large twin study shows that genetics have a major influence on whether attention deficit/hyperactivity disorder symptoms decrease or persist as children grow older. [More]
Study paves way for greater understanding of Attention Deficit Hyperactivity Disorder

Study paves way for greater understanding of Attention Deficit Hyperactivity Disorder

Researchers at the Angiocardioneurology Department of the Neuromed Scientific Institute for Research, Hospitalisation and Health Care of Pozzilli (Italy), have found, in animal models, that the absence of a certain enzyme causes a syndrome resembling the Attention Deficit Hyperactivity Disorder (ADHD). [More]
Prevalence of ADHD decreases substantially as altitude increases

Prevalence of ADHD decreases substantially as altitude increases

Recent research has linked the thin air of higher elevations to increased rates of depression and suicide. But a new study shows there's also good news from up in the aspens and pines: The prevalence of attention deficit hyperactivity disorder (ADHD) decreases substantially as altitude increases. [More]
Antipsychotic drugs may elevate child's risk for weight gain, type II diabetes

Antipsychotic drugs may elevate child's risk for weight gain, type II diabetes

Today in JAMA Pediatrics, researchers from The Children's Hospital of Philadelphia's (CHOP) PolicyLab published the largest study to date documenting the significant risks to children's health associated with prescription antipsychotics, a powerful a class of medications used to treat mental and behavioral health disorders. [More]
Long-term effects of using cognitive-enhancing drugs by healthy people need to be determined

Long-term effects of using cognitive-enhancing drugs by healthy people need to be determined

The government, pharmaceutical industry, and national medical organisations need to work together to look at the harms and benefits of long-term use of cognitive-enhancing drugs by healthy individuals, say neuroscientists Professor Barbara Sahakian and Dr Sharon Morein-Zamir from the University of Cambridge in the UK, writing in a Personal View in The Lancet Psychiatry journal. [More]
Expansion of medical system has led people to feel less healthy over time, study finds

Expansion of medical system has led people to feel less healthy over time, study finds

Across much of the Western world, 25 years of expansion of the medical system has actually led to people feeling less healthy over time, a new study has found. [More]
Young children, teens at risk for unintentional medicine poisoning

Young children, teens at risk for unintentional medicine poisoning

Nearly half of the 1.34 million calls to poison centers for children each year are related to medicine. In fact, every day, there are more than 1,100 calls about a young child getting into medicine or getting too much medicine. [More]
Tourette syndrome patients may face second psychiatric disorder during their lifetimes

Tourette syndrome patients may face second psychiatric disorder during their lifetimes

A new study of Tourette syndrome (TS) led by researchers from UC San Francisco and Massachusetts General Hospital has found that nearly 86 percent of patients who seek treatment for TS will be diagnosed with a second psychiatric disorder during their lifetimes, and that nearly 58 percent will receive two or more such diagnoses. [More]
Study finds link between fluoridated water and ADHD prevalence

Study finds link between fluoridated water and ADHD prevalence

"Artificial water fluoridation prevalence was significantly positively associated with ADHD prevalence," according to research published in Environmental Health (2/15), reports the Fluoride Action Network (FAN). [More]

ADHD linked to premature death risk

Patients with attention deficit/hyperactivity disorder have a significantly increased mortality rate, especially if they are diagnosed in adulthood, a study published in The Lancet shows. [More]
Vitamin D, omega-3 fatty acids may optimize brain serotonin concentrations and function

Vitamin D, omega-3 fatty acids may optimize brain serotonin concentrations and function

Although essential marine omega-3 fatty acids and vitamin D have been shown to improve cognitive function and behavior in the context of certain brain disorders, the underlying mechanism has been unclear. In a new paper published in FASEB Journal by Rhonda Patrick, PhD and Bruce Ames, PhD of Children's Hospital Oakland Research Institute, serotonin is explained as the possible missing link tying together why vitamin D and marine omega-3 fatty acids might ameliorate the symptoms associated with a broad array of brain disorders. [More]
Declarative memory helps individuals with neurodevelopmental disorders compensate for dysfunction

Declarative memory helps individuals with neurodevelopmental disorders compensate for dysfunction

Individuals with five neurodevelopmental disorders -- autism spectrum disorder, obsessive-compulsive disorder, Tourette syndrome, dyslexia, and Specific Language Impairment -- appear to compensate for dysfunction by relying on a single powerful and nimble system in the brain known as declarative memory. [More]
Middle-school children who consume sweetened energy drinks at increased risk for hyperactivity

Middle-school children who consume sweetened energy drinks at increased risk for hyperactivity

Middle-school children who consume heavily sweetened energy drinks are 66% more likely to be at risk for hyperactivity and inattention symptoms, a new study led by the Yale School of Public Health has found. [More]
Study explores effects of medical marijuana in children and teens with ASD, ADHD

Study explores effects of medical marijuana in children and teens with ASD, ADHD

As medical marijuana becomes increasingly accepted, there is growing interest in its use for children and adolescents with developmental and behavioral problems such as autism spectrum disorders (ASD) and attention-deficit/hyperactivity disorder (ADHD), according to a review in the February Journal of Developmental & Behavioral Pediatrics, the official journal of the Society for Developmental and Behavioral Pediatrics. [More]
EyeBrain raises €1.3 million ($1.47 million) through crowdfunding

EyeBrain raises €1.3 million ($1.47 million) through crowdfunding

EyeBrain, a company that develops markers of cerebral function for neurological and psychiatric disorders and diseases, today announces the conclusion of a new round of funding. A total of €1.3 million ($1.47 million) has been raised with the support of EyeBrain’s shareholders, the Fonds Régional de Co-Investissement d’Ile-de-France (FRCI, regional joint investment fund for the Ile-de-France or Greater Paris area) and the Anaxago crowdfunding platform. [More]
Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm Campbell Memorial Prize for 2015 has been awarded to Miles Congreve (Vice President of Chemistry), Fiona Marshall (Chief Scientific Officer and co-founder) and Malcolm Weir (Chief Executive Officer and co-founder) for the seminal contributions to GPCR drug discovery made by Heptares Therapeutics since the company was founded in 2007. [More]
Advertisement
Advertisement